GEN Exclusives

More »

GEN News Highlights

More »
Mar 6, 2008

Avanir Divests Anthrax mAb Program to Emergent BioSolutions in Deal Worth $1.75M

  • Avanir Pharmaceuticals is selling its portfolio of human monoclonal anthrax antibodies to Emergent BioSolutions. Under terms of the definitive agreement, Avanir could receive up to $1.75 million in upfront and milestone fees as well as royalties on annual net sales upon commercialization.

    The agreement is another step for Avanir in its plan to focus on its late-stage compound in development for diabetic peripheral neuropathic pain and pseudobulbar affect. The firm ended collaborations with Novartis and AstraZeneca about a year ago. The only other development program involving selective cytokine inhibitors was placed on  hold in November 2006.

    “This transaction along with other potential monetization of noncore assets will provide additional nondilutive financing and allow us to continue our focus on the ongoing clinical development of our promising Phase III drug candidate, Zenvia™,” says Keith Katkin, Avanir’s president and CEO.

    With this divestiture, Emergent acquires Avanir’s lead candidate, AVP-21D9, and additional anthrax antibodies. Emergent also receives a limited exclusive license to use Avanir’s Xenerex™ platform to develop future human mAbs targeted against Bacillus anthracis.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...

Unable to get Jobs Listings.

More »

GEN Poll

More » Poll Results »

Biosimilars

Compared to the original biologics, do you think biosimilars run the risks of being less effective and causing more side effects?